Ki-67 proliferation index - Correlation with prognostic parameters and outcome in multiple myeloma

被引:53
作者
Alexandrakis, MG
Passam, FH
Kyriakou, DS
Dambaki, K
Niniraki, M
Stathopoulos, E
机构
[1] Univ Hosp Crete, Dept Haematol, Iraklion, Greece
[2] Univ Hosp Crete, Dept Pathol, Iraklion, Greece
[3] Univ Hosp Crete, Dept Clin Immunol, Iraklion, Greece
[4] Univ Hosp Thessalia, Dept Haematol, Thessaloniki, Greece
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2004年 / 27卷 / 01期
关键词
Ki-67; multiple myeloma; IL-6; IL-10;
D O I
10.1097/01.coc.0000045810.91816.41
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The nuclear protein Ki-67 is a proliferation index, as it is expressed only by dividing cells. In this study, we investigated the clinical significance of Ki-67 determination on bone marrow biopsies of 35 patients with newly diagnosed multiple myeloma (MM). We examined the correlation of Ki-67 with other MM proliferation-related factors: interleukin-6 (IL-6), IL-10, bone marrow infiltration by plasma cells, serum lactate dehydrogenase (LDH), and beta 2 microglobulin (b(2)M). Ki-67 expression was also correlated with the survival rate of the patients. The results showed that Ki-67 expression increases with increasing stage of disease according to Durie-Salmon (classification stage III vs. I and II, p < 0.001). Furthermore, infiltration, IL-6, LDH, and b2M increase significantly with advancing stage of disease (p < 0.004). All parameters studied were significantly higher in patients versus controls. Ki-67 correlated with IL-6 (r: 0.422, p < 0.01), LDH (r: 0.437, p < 0.01), and b(2)M (r: 0.478, p < 0.004). There was a marked difference in survival between patients with MM with Ki-67 greater than 8% and patients with Ki-67 less than 8%, in favor of the latter (p < 0.07). We conclude that Ki-67 determination during routine pathological analysis of bone marrow in newly diagnosed MM could provide useful information about the proliferative activity and prognosis of the disease.
引用
收藏
页码:8 / 13
页数:6
相关论文
共 27 条
[1]   Advances in disease biology: Therapeutic implications [J].
Anderson, KC .
SEMINARS IN HEMATOLOGY, 2001, 38 (02) :6-10
[2]  
ANDERSON KC, 1989, BLOOD, V73, P1915
[3]  
Barillé S, 2000, EUR CYTOKINE NETW, V11, P546
[4]  
BATAILLE R, 1992, BLOOD, V80, P733
[5]  
Dalton WS, 1999, SEMIN ONCOL, V26, P23
[6]   HIGH SERUM LACTATE-DEHYDROGENASE LEVEL AS A MARKER FOR DRUG-RESISTANCE AND SHORT SURVIVAL IN MULTIPLE-MYELOMA [J].
DIMOPOULOS, MA ;
BARLOGIE, B ;
SMITH, TL ;
ALEXANIAN, R .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (12) :931-935
[7]   THE BIOLOGICAL AND CLINICAL-SIGNIFICANCE OF THE KI-67 GROWTH FRACTION IN MULTIPLE-MYELOMA [J].
DRACH, J ;
GATTRINGER, C ;
GLASSL, H ;
DRACH, D ;
HUBER, H .
HEMATOLOGICAL ONCOLOGY, 1992, 10 (02) :125-134
[8]  
DURIE BGM, 1980, BLOOD, V55, P364
[9]  
DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO
[10]  
2-U